Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Viridian Therapeutics ( (VRDN) ).
On October 17, 2025, Viridian Therapeutics entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions, selling rights to certain revenue streams in the U.S. for up to $300 million. This agreement includes payments contingent on achieving specific clinical and regulatory milestones for its products VRDN-003 and veligrotug. Additionally, Viridian amended its Loan and Security Agreement with Hercules Capital, securing a new term loan facility of up to $300 million, structured in tranches contingent on regulatory and revenue milestones, with a maturity date set for October 17, 2030.
The most recent analyst rating on (VRDN) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
Viridian Therapeutics’ stock score is driven by positive technical indicators and promising corporate events, offset by weak financial performance and valuation concerns. The company’s strategic partnerships and successful trial results provide growth potential, but financial challenges remain a significant risk.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics, Inc. is a company operating in the biotechnology industry, focusing on developing therapies for rare diseases. The company is primarily engaged in clinical trials and the development of products such as VRDN-003 and veligrotug, targeting significant milestones in the healthcare market.
Average Trading Volume: 818,321
Technical Sentiment Signal: Buy
Current Market Cap: $1.98B
Find detailed analytics on VRDN stock on TipRanks’ Stock Analysis page.